Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 5/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.56 |
| ▸ | BRD4 | O60885 | 6/20 | 0.52 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.48 |
| ▸ | BRD2 | P25440 | 1/20 | 0.48 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.48 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.48 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30693774 | 1.00 | HSPB1 (0.67) | HSPB1PTGS2PTGS1BRD4TRIM24 | |
| SCHEMBL9453022 | 0.87 | PTPN1 (0.51) | HSPB1 | |
| SCHEMBL15068192 | 0.86 | HSPB1 (0.67) | HSPB1BRD4ATMTDP1 | |
| SCHEMBL20155456 | 0.80 | PTGS2 (0.61) | PTGS2PTGS1BRD4TRIM24BRD2 | |
| SCHEMBL25287811 | 0.80 | EPAS1 (0.47) | HSPB1PTGS2PTGS1 | |
| SCHEMBL1341961 | 0.80 | HSPB1 (0.75) | HSPB1ATMTDP1 | |
| SCHEMBL1341447 | 0.80 | L3MBTL1 (0.66) | HSPB1BRD4TDP1 | |
| SCHEMBL20160408 | 0.79 | HSPB1 (0.72) | HSPB1ATMTDP1 | |
| SCHEMBL10960022 | 0.79 | HSPB1 (0.68) | HSPB1ATMTDP1 | |
| SCHEMBL15067648 | 0.79 | PTGS2 (0.56) | PTGS2PTGS1BRD4TRIM24BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-08-05 | — | — | US | disclosed |
| CN-106986872-B | Bromodomain inhibitors | 艾伯维公司 | 2020-04-21 | — | — | CN | disclosed |
| US-20190084981-A1 | Bromodomain Inhibitors | ABBVIE INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-10131657-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180296566-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2018-10-18 | — | — | US | disclosed |
| US-9957263-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2018-05-01 | — | — | US | disclosed |
| EP-2797918-B1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20160272630-A1 | Bromodomain Inhibitors | ABBVIE INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160185769-A1 | Bromodomain Inhibitors | ABBVIE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160143916-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2016-05-26 | — | — | US | disclosed |
| EP-3013828-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-3013827-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-05-04 | — | — | EP | disclosed |
| US-9296741-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2016-03-29 | — | — | US | disclosed |
| WO-2014206345-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014206150-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| EP-2797918-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-06-12 | — | — | US | disclosed |
| WO-2013097601-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296566-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | HSPB1 2386/4885PTGS2 1807/4885PTGS1 450/4885 |
| US-20190084981-A1 | Bromodomain Inhibitors | BRD4, BRD1, BRD3 | HSPB1 2017/4885PTGS2 2238/4885PTGS1 475/4885 |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | HSPB1 2386/4885PTGS2 1807/4885PTGS1 450/4885 |
| US-10131657-B2 | Bromodomain inhibitors | BRD1, BRD4, BRD3 | HSPB1 2019/4885PTGS2 2097/4885PTGS1 401/4885 |
| US-20160272630-A1 | Bromodomain Inhibitors | BRD4, BRDT, EP300 | HSPB1 890/4885PTGS2 1013/4885PTGS1 385/4885 |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | HSPB1 2386/4885PTGS2 1807/4885PTGS1 450/4885 |
| US-20160185769-A1 | Bromodomain Inhibitors | BRD1, BRD4, BRD3 | HSPB1 2019/4885PTGS2 2097/4885PTGS1 401/4885 |
| US-20160143916-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | HSPB1 2386/4885PTGS2 1807/4885PTGS1 450/4885 |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | HSPB1 2386/4885PTGS2 1807/4885PTGS1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.